---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-015545"
form_type: "8-K"
ticker: null
cik: "0001671284"
company_name: "NeueHealth, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:26:05.514537+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeueHealth secures $30M incremental term loan from NEA; issues penny warrants

## Summary
- Incremental term loan commitment of $30M from NEA lenders under existing credit agreement.
- Issues warrants to purchase up to 1,113,563 shares of common stock at $0.01 per share.
- Proceeds to support general corporate purposes and 2024 strategic priorities.
- Audit Committee waived shareholder vote on warrant issuance, citing financial viability; NYSE approved exception.
- NEA gains right to appoint one Board member after the 2024 annual meeting if certain thresholds met.

## SEC filing metadata
- accession: 0001628280-24-015545
- form_type: 8-K
- cik: 0001671284
- company_name: NeueHealth, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671284/000162828024015545/0001628280-24-015545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671284/000162828024015545/bhg-20240408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-015545
- JSON: https://secwatch.observer/filing/0001628280-24-015545.json
- Plain text: https://secwatch.observer/filing/0001628280-24-015545.txt

## Key facts
- Debt Financings
  NeueHealth, Inc. incurred term loan of $30.0 million with NEA 18, New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P..
  - Instrument: term loan
  - Principal: $30.0 million
  - Counterparty: NEA 18, New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P.
  - Event: incurrence
  source text: to date, and as amended by Incremental Amendment No. 2, the “Amended Credit Agreement”) to provide for a term loan commitment increase in an aggregate principal amount of $30.0 million (the “Commitment Increase”) by the NEA Lenders under the Amended Credit Agreement. Loans under the Commitment Increase will have the same terms as loans under the original term
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671284/000162828024015545/0001628280-24-015545-index.htm
- Material Agreements
  NeueHealth, Inc. amended Incremental Amendment No. 2 with NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P., New Enterprise Associates 15, L.P. valued at $30.0 million (effective 2024-04-08).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P., New Enterprise Associates 15, L.P.
  - Value: $30.0 million
  - Effective: 2024-04-08
  source text: On April 8, 2024, (i) NeueHealth, Inc. (the “Company”) and (ii) NEA 18 Venture Growth Equity, L.P. (“NEA 18”), New Enterprise Associates 17, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 15, L.P. (collectively, the “NEA Lenders”) entered into Incremental Amendment No. 2 (“Incremental Amendment No. 2”) to the Credit Agreement, dated as of August 4, 2023, between the Company and NEA 18 (as amended to date, and as amended by Incremental Amendment No. 2, the “Amended Credit Agreement”) to provide for a term loan commitment increase in an aggregate principal amount of $30.0 million (the “Commitment Increase”) by the NEA Lenders under the Amended Credit Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671284/000162828024015545/0001628280-24-015545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.